Get the Stockscreener App
7.77
1.15%
-0.09
After Hours:
7.77
Neogenomics Inc stock is traded at $7.77, with a volume of 1.15M.
It is down -1.15% in the last 24 hours and down -20.88% over the past month.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
See More
Previous Close:
$7.86
Open:
$7.98
24h Volume:
1.15M
Relative Volume:
0.62
Market Cap:
$1.01B
Revenue:
$727.33M
Net Income/Loss:
$-108.03M
P/E Ratio:
-9.2062
EPS:
-0.844
Net Cash Flow:
$-21.78M
1W Performance:
-3.00%
1M Performance:
-20.88%
6M Performance:
-1.21%
1Y Performance:
-21.99%
1-Day Range:
$7.68
$8.10
1-Week Range:
$7.68
$8.34
52-Week Range:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Name
Neogenomics Inc
Sector
Industry
Phone
(239) 768-0600
Address
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
7.77 | 1.02B | 727.33M | -108.03M | -21.78M | -0.844 |
TMO
Thermo Fisher Scientific Inc
|
490.77 | 182.14B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
187.15 | 134.43B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
575.72 | 45.40B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.98 | 32.27B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
302.32 | 29.62B | 3.17B | 642.63M | 516.49M | 10.77 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-29-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-15-25 | Initiated | Guggenheim | Neutral |
| Apr-30-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jan-13-25 | Downgrade | The Benchmark Company | Buy → Hold |
| Dec-10-24 | Initiated | Jefferies | Buy |
| May-01-24 | Resumed | Craig Hallum | Buy |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Aug-21-23 | Upgrade | Stephens | Equal-Weight → Overweight |
| May-16-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-09-23 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-24-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-01-23 | Upgrade | Needham | Hold → Buy |
| Aug-26-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-22-22 | Downgrade | Needham | Buy → Hold |
| Jun-03-22 | Initiated | Piper Sandler | Overweight |
| Mar-29-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-29-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-18-22 | Resumed | Stephens | Overweight |
| Dec-16-21 | Initiated | Cowen | Outperform |
| Nov-05-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-14-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-03-21 | Initiated | Goldman | Buy |
| Feb-25-21 | Resumed | Needham | Buy |
| Feb-25-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-28-21 | Initiated | Truist | Buy |
| Dec-11-20 | Resumed | BTIG Research | Buy |
| Oct-28-20 | Reiterated | Needham | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Aug-28-20 | Initiated | Guggenheim | Buy |
| Jul-29-20 | Reiterated | Needham | Buy |
| Jun-25-20 | Initiated | BofA/Merrill | Buy |
| Apr-21-20 | Resumed | Stephens | Overweight |
| Mar-02-20 | Resumed | Craig Hallum | Buy |
| Feb-28-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jan-23-20 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-30-19 | Reiterated | Needham | Buy |
| May-01-19 | Reiterated | Needham | Buy |
| Mar-29-19 | Reiterated | Needham | Buy |
| Jan-03-19 | Initiated | Needham | Buy |
| Oct-24-18 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Aug-21-18 | Initiated | Leerink Partners | Outperform |
| May-02-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-11-17 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-24-17 | Initiated | Gabelli & Co | Buy |
| Dec-15-16 | Initiated | Cantor Fitzgerald | Overweight |
View All
Neogenomics Inc Stock (NEO) Latest News
Dip Buying: Whats the analyst consensus on NeoGenomics Inc2026 Selloffs & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
NeoGenomics, Inc. (NASDAQ: NEO) Q4 2025 earnings call transcript - MSN
NeoGenomics invites engagement on innovation in oncology at USCAP event - Traders Union
NeoGenomics slides more than 5% despite fourth-quarter earnings beat - MSN
Aug PreEarnings: Is NeoGenomics Inc stock a falling knife or bargain buyTake Profit & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Aug Retail: Is NeoGenomics Inc gaining market share2026 WrapUp & Fast Entry High Yield Tips - baoquankhu1.vn
Aug Chart Watch: Can NeoGenomics Inc deliver alpha2026 Institutional Moves & Smart Allocation Stock Reports - baoquankhu1.vn
NEO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
NeoGenomics (NEO) launches RaDaR ST to capture share in $20B MRD market - MSN
Discipline and Rules-Based Execution in NEO Response - Stock Traders Daily
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Medicare Coverage for PanTracer LBx Liquid Biopsy Could Be A Game Changer For NeoGenomics (NEO) - simplywall.st
NeoGenomics (NEO) Launches RaDaR ST to Capture Share in $20B MRD Market - Insider Monkey
11 Most Buzzing Stocks to Buy with the Highest Upside Potential - Insider Monkey
NeoGenomics offers preview of booth presence at USCAP2026 - Traders Union
NeoGenomics Beats Investor Suit Over Growth Driver Claims - Law360
Will Medicare Coverage for PanTracer LBx Liquid Biopsy Shift NeoGenomics' (NEO) Diagnostic Narrative? - Yahoo Finance
NeoGenomics, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Challenges - Markets Mojo
Assessing NeoGenomics (NEO) Valuation After Recent Share Price Weakness - simplywall.st
NeoGenomics’ PanTracer LBx test receives Medicare coverage By Investing.com - Investing.com Australia
NEO NeoGenomics, Inc. Maintained: Cowen Buy, William Blair Market Perform Mar 2026 - Meyka
NeoGenomics, Natera, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know - Yahoo Finance
NeoGenomics, Natera, and Amphastar Pharmaceuticals shares skyrocket, what you need to know - MSN
NeoGenomics Gets Dismissal of Cancer Test Misrepresentation Suit - Bloomberg Law News
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling - BioSpace
William Blair reiterates Market Perform on Neogenomics stock after Medicare coverage decision - Investing.com Australia
Neogenomics stock gets Medicare coverage for blood-based test By Investing.com - Investing.com Australia
Neogenomics stock gets MolDX reimbursement for cancer test By Investing.com - Investing.com Australia
Neogenomics stock gets Medicare coverage for blood-based test - Investing.com
NeoGenomics test gains Medicare coverage for cancer care - Gulfshore Business
NeoGenomics’ PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biop - pharmiweb.com
Neogenomics stock gets MolDX reimbursement for cancer test - Investing.com
Neogenomics IncPantracer Lbx Test Receives Medicare Coverage Under CMS Moldx Program - TradingView
NeoGenomics’ PanTracer LBx test receives Medicare coverage - Investing.com
NeoGenomics, Inc. $NEO Stock Position Increased by First Light Asset Management LLC - MarketBeat
Silverback Asset Management LLC Invests $1.55 Million in NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics to present at NextGen Omics Spatial and Data U.S. 2026 on immunotherapy resistance mapping - Traders Union
Liquid Biopsy Market to Reach US$28.20 Billion by 2033 at 12.8% - openPR.com
NeoGenomics (NEO) Price Target Increased by 21.45% to 12.44 - MSN
NeoGenomics announces launch of new cancer assay PanTracer Pro - MSN
Trend Review: Can NeoGenomics Inc keep up with sector leadersQuarterly Trade Summary & Weekly Return Optimization Alerts - baoquankhu1.vn
NeoGenomics (NASDAQ:NEO) Stock Price Down 7.9%Should You Sell? - MarketBeat
Greenhouse Funds LLLP Acquires 789,510 Shares of NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics at Leerink Conference: Strategic Growth Focus By Investing.com - Investing.com India
Neogenomics Inc Stock (NEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.19%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):